There are about 150 different types of ectodermal dysplasia, each of which are genetic conditions affecting the development of skin, teeth, hair, nail, exocrine and sebaceous glands. Hypohidrotic ectodermal dysplasia (HED) is the most common form of ED, and the vast majority of HED cases are the X-linked form (XLHED) – 95% of males with HED have XLHED.1
Clinical diagnosis of XLHED is typically based on the triad of hypo- or anhidrosis, oligo- or anodontia and hypotrichosis,2 and genetic testing is available. Many medical specialties may have an important opportunity for diagnostic suspicion – including dentists, dermatologists, general practitioners, and their pediatric counterparts, as well as obstetricians/gynecologists, geneticists, and genetic counselors.
Though the clinical spectrum is fully expressed in affected males, females are heterozygous and present with more heterogeneous and often less severe phenotypes. Natural history suggests that ≥50% of females with the XLHED mutation have signs or symptoms that can be detected through interview and clinical examination, including:2
XLHED Genetics
Every patient affected by XLHED has a 50% chance of passing the mutation to their children. As with other X-linked disorders, males with the mutation have a fully affected phenotype, while females are heterozygous and have a variable phenotype.
If you suspect XLHED in any of your patients, they may wish to contact an ectodermal dysplasia patient advocacy group for genetic testing. Women with the XLHED mutation who are pregnant or planning for pregnancy may be eligible for the Edelife clinical trial.
XLHED Inheritance (X-linked)
Example: mother carries XLHED mutation to son
X, Y = unaffected genes
Because of X-linked genetics, boys inheriting XLHED from their mother are most likely to be fully affected
Early suspicion and referral are essential. Contact an Edelife clinical site to refer a patient or request more information.
References: 1. Deshmukh S, Prashanth S. Ectodermal Dysplasia: A Genetic Review. Int J Clin Pediatr Dent 2012; 5(3):197-202. 2. Fete M, Hermann J, Behrens J, Huttner KM. 2014. X-linked hypohidrotic ectodermal dysplasia (XLHED): Clinical and diagnostic insights from an international patient registry. Am J Med Genet Part A 164A:2437–2442. 3. Körber, I.; Klein, O.D.; Morhart, P.; Faschingbauer, F.; Grange, D.K.; Clarke, A.; Bodemer, C.; Maitz, S.; Huttner, K.; Kirby, N.; et al. Safety and immunogenicity of Fc-EDA, a recombinant ectodysplasin A1 replacement protein, in human subjects. Br. J. Clin. Pharmacol. 2020, 86, 2063–2069.
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.
This information is presented only for providing overview information about a clinical trial with an investigational product. It should not be construed as a recommendation for an unapproved use.
I certify that I am a Healthcare Professional and I have read the information above:
This is a website about the Edelife Clinical Trial dedicated to Healthcare Professionals.